Tamoxifen Treatment and Risk of Endometrial Cancer: An Overview

This is the authors' abstract. We don't add key points for this paper.

For several decades, tamoxifen has proven effective in reducing recurrence and mortality for early and metastatic breast cancer with positive estrogen receptors, and has been proven to be beneficial in preventing breast cancer in high-risk women. However, tamoxifen has been associated with an increased risk of endometrial cancer by its agonist effects on the endometrium in postmenopausal women. The purpose of this article, through an exhaustive summary of literature, is to provide a better understanding of this relationship and its impact on managed care on patients.